Dactinomycin

This classification denotes an actinomycin antibiotic with the molecular formula C62H86N12O16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1CC1JFE158, chemically known as 4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide but generally known as dactinomycin, which bears US NIH Compound Identifier 2019. European Medicines Agency schedules Dactinomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13528MIG. The term DACTINOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules dactinomycin in its Anatomical Therapeutic Chemical (ATC) Classification. DACTINOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dactinomycin under HS 29419000 and SITC 54139. As of Q4 2014, DACTINOMYCIN remains the US FDA Preferred Term for this commodity. Dactinomycin bears US NLM identifiers UMLS ID C0010934 and NCI Concept Code C412. SMILES: O=C1N2C(CCC2)C(=O)N(CC(=O)N(C(C(C)C)C(=O)OC(C(NC(=O)C2C3NC4C(C(=O)NC5C(=O)NC(C(=O)N6C(CCC6)C(=O)N(CC(=O)N(C(C(C)C)C(=O)OC5C)C)C)C(C)C)CCC(C4OC3C(C(=O)C2N)C)C)C(=O)NC1C(C)C)C)C)C.